Lets take at something that makes a little sense
Biomartin buys Prosensa only for the patents ''to settle patent disputes to partner with Sarepta's drug in Europe only .Makes the best case.. Drops Prosennsa's drug and picks up Sarepta's as a partner and a worked out patent problem,. Even at a 50/50 split biomartin would make out great.
This was feb 2013 ....Duchenne muscular dystrophy patients treated with GlaxoSmithKline's (GSK) experimental drug drisapersen have been hospitalized due to kidney toxicity and low platelet counts, according to a Glaxo scientist who spoke at a research meeting in Rome last Sunday.
Glaxo has disclosed some safety data from early-stage drisapersen clinical trials previously, mainly related to moderate cases of proteinuria (excess protein in the urine) and decreased thrombocytes, which play a role in blood clotting. However, the significance of the adverse events attributed to drisapersen, also known as GSK-2402968, escalated with Sunday's disclosure of hospitalized patients.
Dr. Rohit Batta, global medical leader in Glaxo's neuromuscular rare disease unit, said four Duchenne muscular dystrophy (DMD) patients treated with drisapersen required hospitalization due to thrombocytopenia and that "several" patients with "severe proteinuria" also required hospitalization.
these two leerink guys are very very clueless or just weird
BioMarin Pharmaceutical (BMRN) agreed to purchase Prosensa (RNA) for up to $850 million, in an acquisition Leerink’s Joseph P. Schwartz and Paul Matteis call “courageous.” They explain why:
While somewhat risky ahead of a potential drisapersen advisory committee in mid-2015, we believe the deal is a great bargain for Biomarin who could potentially be paying less than 1.5x peak sales on drisapersen (not including other exon skippers) if the drug is able to attain regulatory approval…
We believe the deal price is a great bargain for BioMarin if it can get drisapersen over the goal line with the FDA/EMA. In our Prosensa model we derive a $37 price target for Prosensa if drisapersen attains accelerated approval in the US/Europe and approval for Sarepta Therapeutics’ (SRPT) eteplirsen is delayed until 2016/2017. Our analysis assumes ~$600MM in gross drisapersen sales in 2024 and that the company splits the market with Sarepta Therapeutics in the US and garners majority share in Europe. For BioMarin, this could be conservative if Sarepta Therapeutics is never able to get to market, and eteplirsen’s outlook has recently become less clear after FDA asked Sarepta Therapeutics for more data. Meanwhile, while BioMarin does not market any drugs that are marketed to the same physician call point, we’d expect at least some potential synergies with Prosensa (upside to the above valuation analysis) given the fact that BioMarin has already established a WW rare disease selling infrastructure.
Biomartain also has a market cap of over 12 billion and they aint worth that.They dont have monies to fight a patent.If i were a good chess player i would guess that Shire or a like Company is talking to Sarepta...
no other reason to buy Prosensa for change unless you want it all..Figure on all exons and total world wide sales of dmd drugs it would be about 6 billion a year in sales, not counting all the other diseases and Sarepta platforms....wow
Prosensa's drug does not work and is toxic and what you are talking about is only in the EU..take note also this is only about exon 51 in the eu and you can use a different exon and still correct that exon 51,it is ways around that.
Any good Analyst can see this .Good gosh
Prosensa sold for nothing,the patent estate was worth about what they sold for.Any one with any good sense can see that Prosensa's dmd drug is not good for long term dosing just short term targets ..Could be that Biomartin is after Sarepta as well.
They want those other patents and prosensa sold for nothing...